Today in Barcelona, Spain, Johnson & Johnson (NYSE: JNJ) revealed that RYBREVANT®, a combination therapy, has been shown to prolong survival and notably decrease prevalent EGFR and MET resistance mutations typically found in osimertinib-based treatments. The data stems from recent analyses conducted on the Phase 3 MARIPOSA study. This development offers promising results in the fight against cancers with these specific mutations, marking a significant advancement in treatment efficacy and patient outcomes.